<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370564</url>
  </required_header>
  <id_info>
    <org_study_id>IPC</org_study_id>
    <nct_id>NCT01370564</nct_id>
  </id_info>
  <brief_title>Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures</brief_title>
  <acronym>IPC</acronym>
  <official_title>Feasibility of an Integrated Patient Care (IPC) System Using Daily Filling Pressures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This chronic, prospective, non-randomized feasibility study is designed to evaluate the
      Integrated Patient Care (IPC) concept in subjects who already have either a Medtronic
      Chronicle Implantable Hemodynamic Monitor (IHM) or Chronicle Implantable Cardioverter
      Defibrillator (ICD) device implanted, and are currently enrolled in the Chronicle Offers
      Management to Patients with Advanced Signs &amp; Symptoms of Heart Failure (COMPASS-HF) Extension
      Phase Study (IDE # G020304). The purpose of the study is to use daily cardiac filling
      pressures from the Chronicle device to provide timely medication adjustments (diuretics) to
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be asked to transmit to the CareLink Network daily. Data specific to this study
      (subject's daily estimated Pulmonary Arterial Diastolic (ePAD) pressure values) will be
      extracted from the CareLink database and transferred to the IPC clinician website.

      As each subject is enrolled, clinicians at each participating site will determine the
      appropriate target pressure range for each subject based on a review of the subject's
      pressure data. Each day after enrollment, the subject's current pressure data will be
      compared to a target pressure range that the clinician sets for that subject.

      The patient instruction set (PtIS) is limited to a daily diuretic prescription and associated
      supplements, per physician discretion. The PtIS should not include adjustments of non-heart
      failure medications and should not include heart failure medications that are not indicated
      for day-to-day adjustments (e.g. ACE-Inhibitors, Angiotensin Receptor Blockers (ARBs), and
      Beta-Blockers). The PtIS will be sent from the IPC clinician website to the subject through a
      Patient Home Monitor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the Technical Feasibility of the Network Based IPC System</measure>
    <time_frame>Baseline through Completion/Exit (an average of 3 months)</time_frame>
    <description>The proportion of study days a PtIS is based on the subjects' daily pressure state</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the Rate of IPC Setup System Changes</measure>
    <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
    <description>The frequency of changes in the IPC setup during the study (an average of 3-months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantify Subject Compliance to Daily PtIS</measure>
    <time_frame>Baseline through Completion/Exit (on average 3-months)</time_frame>
    <description>The proporition of IPC days study subjects indicated they complied with their PtIS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Changes in Clinical Markers of Heart Failure and Kidney Function</measure>
    <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
    <description>Changes in brain natriuretic peptide from baseline to study exit (an average of 3-months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summarize Adverse Events</measure>
    <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
    <description>All serious adverse events, cardiovascular adverse events, and event related to the IPC system will be documented and summarized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Changes in Clinical Markers of Heart Failure and Kidney Function</measure>
    <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
    <description>Changes in estimated glomular filtration rate from baseline to study exit (an average of 3-months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate Changes in Clinical Markers of Heart Failure and Kidney Function</measure>
    <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
    <description>Changes in blood urea nitrogen from baseline to study exit (an average of 3-months).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Daily diuretic adjustment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diuretics</intervention_name>
    <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
    <arm_group_label>Daily diuretic adjustment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients implanted with a Chronicle IHM device (Model 9520, Model 9520B) or Chronicle
             ICD device (Model 7286)

          -  Patients who have been prescribed daily diuretic therapy for the management of heart
             failure

          -  Patients currently participating in the COMPASS-HF Extension Phase Study (IDE
             #G020304)

          -  Patients willing and able to give informed consent

        Exclusion Criteria:

          -  Patients with non-physiologic Right Ventricular (RV) pressure values

          -  Patients who have diuretic resistance

          -  Patients who have an estimated Glomerular Filtration Rate(eGFR) &lt;30 ml/min (recorded
             within the last six months)

          -  Patients who have a Chronicle IHM device (Model 9520) that was implanted as part of
             the Pulmonary Arterial Hypertension (PAH) Pilot Study (IDE #G020303)

          -  Patients who do not have the ability to actively participate in the management of
             their own heart failure care (determine by physician discretion)(e.g. patient does not
             have ability to operate study equipment, patient does not have a history of compliance
             to sending CareLink transmissions)

          -  Patients who have a reasonable probability of needing a device replacement during the
             study (approximately two months)

          -  Patients enrolled or planning to participate in a concurrent drug and/or device study
             during the course of this clinical trial

          -  Patient who are pregnant (all females of child-bearing potential must have a negative
             pregnancy test within 1 week of enrollment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Adamson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oklahoma Cardiovascular Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cardiovascular Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Cardiovascular</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>June 8, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <results_first_submitted>February 6, 2018</results_first_submitted>
  <results_first_submitted_qc>June 12, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 11, 2018</results_first_posted>
  <last_update_submitted>June 12, 2018</last_update_submitted>
  <last_update_submitted_qc>June 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Cardiac filling pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diuretics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Daily Diuretic Adjustment</title>
          <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Daily Diuretic Adjustment</title>
          <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.2" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New York Heart Association Classification</title>
          <description>The New York Heart Association (NYHA) Functional Classification classifies the extent of heart failure. It places patients in one of four categories based on how much they are limited during physical activity.
Class I: Cardiac disease, but no symptoms and no limitation in ordinary physical activity, Class II: Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
Class III: Marked limitation in activity due to symptoms Class IV: Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Class I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Class IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Characterize the Technical Feasibility of the Network Based IPC System</title>
        <description>The proportion of study days a PtIS is based on the subjects' daily pressure state</description>
        <time_frame>Baseline through Completion/Exit (an average of 3 months)</time_frame>
        <population>The analysis population is the total number of study participants. For each study subject, the number of days in which the IPC system delivered a patient instruction set based on the subject's pressure state as measured by the Chronicle ICD/IHM pressure sensor.</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Diuretic Adjustment</title>
            <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize the Technical Feasibility of the Network Based IPC System</title>
          <description>The proportion of study days a PtIS is based on the subjects' daily pressure state</description>
          <population>The analysis population is the total number of study participants. For each study subject, the number of days in which the IPC system delivered a patient instruction set based on the subject's pressure state as measured by the Chronicle ICD/IHM pressure sensor.</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Days</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Days</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1586"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72" lower_limit="65" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>There was no specific hypothesis tested. The method of Rao and Scott for clustered binary data was used to construct a point estimate and 95% confidence interval for the number of days during the follow-up period across all subjects in which the patient instruction set was based on the subject's pressure state as measured by the Chronicle IHM/ICD system.</non_inferiority_desc>
            <param_type>Rao-Scott estimator for clustered data</param_type>
            <param_value>72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>65</ci_lower_limit>
            <ci_upper_limit>78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize the Rate of IPC Setup System Changes</title>
        <description>The frequency of changes in the IPC setup during the study (an average of 3-months).</description>
        <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
        <population>The analysis population is the total number of study participants. For each study subject, the number of changes to the IPC setup were obtained</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Diuretic Adjustment</title>
            <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize the Rate of IPC Setup System Changes</title>
          <description>The frequency of changes in the IPC setup during the study (an average of 3-months).</description>
          <population>The analysis population is the total number of study participants. For each study subject, the number of changes to the IPC setup were obtained</population>
          <units>changes per day</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="0.1" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantify Subject Compliance to Daily PtIS</title>
        <description>The proporition of IPC days study subjects indicated they complied with their PtIS.</description>
        <time_frame>Baseline through Completion/Exit (on average 3-months)</time_frame>
        <population>The analysis population is the total number of study participants. For each study subject, the number of days in which the subject indicated that they followed their PtIS</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Diuretic Adjustment</title>
            <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantify Subject Compliance to Daily PtIS</title>
          <description>The proporition of IPC days study subjects indicated they complied with their PtIS.</description>
          <population>The analysis population is the total number of study participants. For each study subject, the number of days in which the subject indicated that they followed their PtIS</population>
          <units>proportion of compliant days</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.994" lower_limit="0.988" upper_limit="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate Changes in Clinical Markers of Heart Failure and Kidney Function</title>
        <description>Changes in brain natriuretic peptide from baseline to study exit (an average of 3-months).</description>
        <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
        <population>Subjects with brain natriuretic peptide values at baseline and study completion (3-month visit) visits</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Diuretic Adjustment</title>
            <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Changes in Clinical Markers of Heart Failure and Kidney Function</title>
          <description>Changes in brain natriuretic peptide from baseline to study exit (an average of 3-months).</description>
          <population>Subjects with brain natriuretic peptide values at baseline and study completion (3-month visit) visits</population>
          <units>pg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-44.4" spread="388.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summarize Adverse Events</title>
        <description>All serious adverse events, cardiovascular adverse events, and event related to the IPC system will be documented and summarized.</description>
        <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
        <population>All 21 subjects participating in the IPC study</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Diuretic Adjustment</title>
            <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
          </group>
        </group_list>
        <measure>
          <title>Summarize Adverse Events</title>
          <description>All serious adverse events, cardiovascular adverse events, and event related to the IPC system will be documented and summarized.</description>
          <population>All 21 subjects participating in the IPC study</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Event</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPC Related Adverse Events</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PtIS Related Adverse Events</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure Related Adverse Event</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular Related Adverse Event</title>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate Changes in Clinical Markers of Heart Failure and Kidney Function</title>
        <description>Changes in estimated glomular filtration rate from baseline to study exit (an average of 3-months).</description>
        <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
        <population>Subjects with lestimated glomular filtration rate values available at the baseline and study exit (3-month) visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Diuretic Adjustment</title>
            <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Changes in Clinical Markers of Heart Failure and Kidney Function</title>
          <description>Changes in estimated glomular filtration rate from baseline to study exit (an average of 3-months).</description>
          <population>Subjects with lestimated glomular filtration rate values available at the baseline and study exit (3-month) visit.</population>
          <units>mL/min per 1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimate Changes in Clinical Markers of Heart Failure and Kidney Function</title>
        <description>Changes in blood urea nitrogen from baseline to study exit (an average of 3-months).</description>
        <time_frame>Baseline through Completion/Exit (an average of 3-months)</time_frame>
        <population>Subjects with blood urea nitrogen values at both the baseline and study exit visits</population>
        <group_list>
          <group group_id="O1">
            <title>Daily Diuretic Adjustment</title>
            <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate Changes in Clinical Markers of Heart Failure and Kidney Function</title>
          <description>Changes in blood urea nitrogen from baseline to study exit (an average of 3-months).</description>
          <population>Subjects with blood urea nitrogen values at both the baseline and study exit visits</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All serious adverse events, cardiovascular related adverse events, and events related to the IPC system were captured from study enrollment through the study exit (approximately 60 days post-enrollment)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Daily Diuretic Adjustment</title>
          <description>Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Diuretics: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The IPC study was a research feasibility study and was not powered to test any specific stastistical hypotheses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Todd Fonseca, VP Clinical</name_or_title>
      <organization>Medtronic</organization>
      <phone>763-526-8151</phone>
      <email>todd.fonseca@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

